<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>INAVO120 &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/inavo120/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 27 Oct 2026 06:27:17 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>INAVO120 &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Even After a 61% Price Cut, a New Breast Cancer Drug Fails China&#8217;s Cost-Effectiveness Test</title>
		<link>https://bioengineer.org/even-after-a-61-price-cut-a-new-breast-cancer-drug-fails-chinas-cost-effectiveness-test/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 06:27:17 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[cost-effectiveness]]></category>
		<category><![CDATA[fulvestrant]]></category>
		<category><![CDATA[ICER]]></category>
		<category><![CDATA[INAVO120]]></category>
		<category><![CDATA[inavolisib]]></category>
		<category><![CDATA[National Reimbursement Drug List]]></category>
		<category><![CDATA[palbociclib]]></category>
		<category><![CDATA[pharmacoeconomics]]></category>
		<category><![CDATA[PIK3CA]]></category>
		<category><![CDATA[quality-adjusted life-year]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=460575</guid>

					<description><![CDATA[A pharmacoeconomic analysis using Asian cohort data from the INAVO120 trial finds that inavolisib plus palbociclib/fulvestrant is not cost-effective nationally in China despite a 61% negotiated price cut, though it may be affordable in wealthier provinces.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">460575</post-id>	</item>
	</channel>
</rss>
